Trials / Completed
CompletedNCT03905265
Dose-finding Study of Moxidectin for Treatment of Scabies
A Phase II, Randomized, Double-blind, Parallel Group Dose Finding Study of Single Oral Doses of Moxidectin in Adults With Scabies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Medicines Development for Global Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The effective dose of moxidectin to treat human scabies is not known. This study aims to provide proof of concept that a single dose of moxidectin is effective in eliminating the scabies parasite in humans and to enable the determination of an optimal dose of moxidectin for treatment of scabies for further clinical studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Moxidectin Oral Product | The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required |
Timeline
- Start date
- 2020-01-13
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
- First posted
- 2019-04-05
- Last updated
- 2023-09-22
- Results posted
- 2023-09-22
Locations
5 sites across 3 countries: Australia, Austria, France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03905265. Inclusion in this directory is not an endorsement.